Try this one...
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2020 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced that the U.S. District Court of New Jersey found the device patent claims (U.S. Patent No. 9,526,844) asserted by Sanofi against Mylan’s insulin glargine product not infringed and invalid for lack of written description.
Does Mylan make insulin?
Mylan announced Thursday that the U.S. Patent and Trademark Appeal Board had ruled in its favor, allowing the Canonsburg-based pharmaceutical company to continue making a generic insulin glargine vial. Dec 13, 2018
Mylan wins lawsuit over Sanofi insulin formulation patents ...